Capricor Therapeutics, Inc.
CAPR Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$6.10
KIRA · Stoqly’s AI analyst, in plain words
- Capricor Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Capricor Therapeutics, Inc. lost $105M in fiscal 2025.
- Free cash flow was −$72.7M in fiscal 2025, — of revenue.
Market cap
$353M
P/E
—
Revenue
$0.0M
Net income
−$105M
Free cash flow
−$72.7M
Operating margin
—
Capricor Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$105M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Capricor Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- CAPRICOR THERAPEUTICS, INC.
- CIK
- 0001133869
Capricor Therapeutics, Inc. · CAPR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $2.6M | $25.2M | $22.3M | $0.0M |
| Revenue growth | −21.1% | 941.9% | 886.8% | −11.5% | −100.0% |
| Operating margin | −8,549.8% | −1,163.9% | −95.6% | −191.1% | — |
| Net income | −$20.0M | −$29.0M | −$22.3M | −$40.5M | −$105M |
| Net margin | −8,175.8% | −1,137.4% | −88.5% | −181.7% | — |
| Diluted EPS | −$0.87 | −$1.18 | −$0.83 | −$1.15 | −$2.26 |
| Cash | |||||
| Cash from operations | −$16.8M | $4.9M | −$25.6M | −$40.0M | −$69.8M |
| Capital expenditure | $1.2M | $2.0M | $1.3M | $1.2M | $2.9M |
| Free cash flow | −$18.0M | $2.9M | −$26.9M | −$41.2M | −$72.7M |
| FCF margin | −7,352.2% | 114.3% | −106.9% | −184.8% | — |
| Share count change | 48.3% | 6.3% | 9.1% | 31.5% | 32.0% |
| Debt and strength | |||||
| Cash and short-term investments | $34.9M | $41.4M | $39.5M | $152M | $318M |
| Shareholders' equity | $31.4M | $11.8M | $22.6M | $145M | $306M |
| Current ratio | 8.8x | 1.8x | 1.6x | 7.8x | 9.0x |
| Interest coverage | — | — | — | — | −35.5x |
| Returns and quality | |||||
| Return on equity | −67.2% | −134.5% | −129.6% | −48.2% | −46.6% |
| Return on tangible equity | −63.8% | −246.2% | −98.6% | −27.8% | −34.4% |
| Piotroski F-score | 1 | 3 | 2 | 3 | 2 |
| Altman Z'' | −3.5 | −10.1 | −8.8 | 6.1 | 6.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$8.4M
3 insiders
Of sales under plans
100%
$8.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Capricor Therapeutics, Inc. · CAPR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.10 a share, the company is worth $353M.
Source: SEC EDGAR XBRL filings (CIK 0001133869). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.